These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17066499)

  • 1. Virtual screening for PPAR modulators using a probabilistic neural network.
    Derksen S; Rau O; Schneider P; Schubert-Zsilavecz M; Schneider G
    ChemMedChem; 2006 Dec; 1(12):1346-50. PubMed ID: 17066499
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors.
    Liutkus M; Caijo F; Girard AL; Ayral E; Audinot V; Boutin JA; Renard P; Caignard DH; Dacquet C; Ktorza A; Mosset P; Grée R
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):653-72. PubMed ID: 20518620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists.
    Rikimaru K; Wakabayashi T; Abe H; Tawaraishi T; Imoto H; Yonemori J; Hirose H; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
    Bioorg Med Chem; 2012 May; 20(10):3332-58. PubMed ID: 22503460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships of dimeric PPAR agonists.
    Sauerberg P; Mogensen JP; Jeppesen L; Svensson LA; Fleckner J; Nehlin J; Wulff EM; Pettersson I
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1497-500. PubMed ID: 15713415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening.
    Sundriyal S; Bharatam PV
    Eur J Med Chem; 2009 Sep; 44(9):3488-95. PubMed ID: 19268404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.
    Mahindroo N; Peng YH; Lin CH; Tan UK; Prakash E; Lien TW; Lu IL; Lee HJ; Hsu JT; Chen X; Liao CC; Lyu PC; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2006 Oct; 49(21):6421-4. PubMed ID: 17034149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A common building block for the syntheses of amorfrutin and cajaninstilbene acid libraries toward efficient binding with peroxisome proliferator-activated receptors.
    Aidhen IS; Mukkamala R; Weidner C; Sauer S
    Org Lett; 2015 Jan; 17(2):194-7. PubMed ID: 25534018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
    Gani OA; Sylte I
    J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
    Gani OA; Sylte I
    Chem Biol Drug Des; 2008 Jul; 72(1):50-7. PubMed ID: 18554251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of herbal extracts for activation of the human peroxisome proliferator-activated receptor.
    Rau O; Wurglics M; Dingermann T; Abdel-Tawab M; Schubert-Zsilavecz M
    Pharmazie; 2006 Nov; 61(11):952-6. PubMed ID: 17152989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators.
    Kumar R; Mittal A; Ramachandran U
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4613-8. PubMed ID: 17574414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From molecular shape to potent bioactive agents I: bioisosteric replacement of molecular fragments.
    Proschak E; Zettl H; Tanrikulu Y; Weisel M; Kriegl JM; Rau O; Schubert-Zsilavecz M; Schneider G
    ChemMedChem; 2009 Jan; 4(1):41-4. PubMed ID: 19058279
    [No Abstract]   [Full Text] [Related]  

  • 14. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects.
    Carmona MC; Louche K; Lefebvre B; Pilon A; Hennuyer N; Audinot-Bouchez V; Fievet C; Torpier G; Formstecher P; Renard P; Lefebvre P; Dacquet C; Staels B; Casteilla L; Pénicaud L;
    Diabetes; 2007 Nov; 56(11):2797-808. PubMed ID: 17704298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of synthetic sphingolipid analogs as ligands for peroxisome proliferator-activated receptors.
    Tsuji K; Satoh S; Mitsutake S; Murakami I; Park JJ; Li Q; Chang YT; Chung SK; Igarashi Y
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1643-6. PubMed ID: 19237283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential remains for PPAR-targeted drugs.
    Jones D
    Nat Rev Drug Discov; 2010 Sep; 9(9):668-9. PubMed ID: 20811368
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part.
    Kasuga J; Oyama T; Hirakawa Y; Makishima M; Morikawa K; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4525-8. PubMed ID: 18662876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG; Somsák L
    Curr Opin Investig Drugs; 2008 Apr; 9(4):379-95. PubMed ID: 18393105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.
    Parmenon C; Guillard J; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Dacquet C; Ktorza A; Viaud-Massuard MC
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1617-22. PubMed ID: 18255290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.